CBER (Center for Biologics Evaluation and Research) introduces action plan to streamline US regulation of biologic devices
This article was originally published in Clinica
Executive Summary
The FDA has proposed bringing the regulation of biologic devices more in line with the agency's practice in regulating other devices.